KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash from Investing Activities: 2018-2024

Historic Cash from Investing Activities for Royalty Pharma (RPRX) over the last 7 years, with Dec 2024 value amounting to -$2.7 billion.

  • Royalty Pharma's Cash from Investing Activities rose 19.65% to -$958.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year increase of 59.91%. This contributed to the annual value of -$2.7 billion for FY2024, which is 29.20% down from last year.
  • Royalty Pharma's Cash from Investing Activities amounted to -$2.7 billion in FY2024, which was down 29.20% from -$2.1 billion recorded in FY2023.
  • Over the past 5 years, Royalty Pharma's Cash from Investing Activities peaked at -$1.0 billion during FY2022, and registered a low of -$2.8 billion during FY2020.
  • In the last 3 years, Royalty Pharma's Cash from Investing Activities had a median value of -$2.1 billion in 2023 and averaged -$1.9 billion.
  • In the last 5 years, Royalty Pharma's Cash from Investing Activities soared by 44.96% in 2022 and then plummeted by 101.35% in 2023.
  • Over the past 5 years, Royalty Pharma's Cash from Investing Activities (Yearly) stood at -$2.8 billion in 2020, then soared by 32.22% to -$1.9 billion in 2021, then skyrocketed by 44.96% to -$1.0 billion in 2022, then tumbled by 101.35% to -$2.1 billion in 2023, then decreased by 29.20% to -$2.7 billion in 2024.